etanidazole
Small moleculeexperimental
Etanidazole is a nitroimidazole drug that was investigated in clinical trials for its radiosensitizing properties in cancer treatment. Administration of etanidazole results in a decrease of glutathione concentration and inhibits glutathione S-transferase. The result is that tissues become more sensitive to the ionizing radiation. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2001 (NCT00430079)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Loading structure…
SMILES
O=C(Cn1ccnc1[N+](=O)[O-])NCCO- Mol. weight
- 214.18 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEtanidazole ↗
- ChEMBLCHEMBL47405 ↗
Also known as
- etanidazole
- etanidazole
- etanidazole
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00028782 | N/A | Oct 1, 2001 | National Cancer Institute (NCI), University of Pennsylvania |
| NCT00430079 | N/A | Jul 1, 2001 | National Cancer Institute (NCI), University of Pennsylvania |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 2001 |
| University of Pennsylvania | Academic/Hospital | 2 | 0 | 1 | 2001 |
2 organizations
Page 1 / 1